Intrexon granted Ziopharm exclusive, worldwide rights to INXN-3001, INXN-1001 and its UltraVector human in vivo effector platform to develop and commercialize DNA-based therapeutics for oncology

Intrexon Corp.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!; This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Ziopharm Oncology Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$226.3m on 12/31/2010 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!; This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced